ReviewCurrent HIV/AIDS reports2014
HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.
Review in Current HIV/AIDS reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Worldwide Occurrence of HIV-Associated Neurocognitive Disorders and Its Associated Factors: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2022Pooled it
- Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders.Neuropsychology review · 2019Pooled it
- Reliability of White Matter Microstructural Changes in HIV Infection: Meta-Analysis and Confirmation.AJNR. American journal of neuroradiology · 2017Pooled it
- Evolution of changes in cognitive function after the initiation of antiretroviral therapy.AIDS research and therapy · 2016Trial
- HIV expression persists in the cerebrospinal fluid of HIV-associated neurocognitive disorders despite effective ART.Emerging microbes & infections · 2026Article
- Diagnostic accuracy of IHDS and MoCA in screening for HIV-associated neurocognitive disorders among adults living with HIV in Ethiopia.International journal of mental health systems · 2026Article
- Rapid decline of cerebrospinal fluid biomarkers of axonal injury and neuroinflammation after initiation of antiretroviral therapy in HIV.Journal of neurovirology · 2025Article
- Reduction in Brain Parenchymal Volume Correlates with Depression and Cognitive Decline in HIV-Positive Males.Medicina (Kaunas, Lithuania) · 2025Article
- CD14+CD16+ monocyte transmigration across the blood-brain barrier is associated with HIV-NCI despite viral suppression.JCI insight · 2024Article
- Article
- Current clinical presentations of AIDS dementia in a tropical environment: study of 26 observations in the neurology department of the University Hospital of Conakry.European journal of medical research · 2023Article
- Neuropsychological Test Norms for the Assessment of HIV-Associated Neurocognitive Impairment Among South African Adults.AIDS and behavior · 2023Article
- Assessment and Diagnosis of HIV-Associated Dementia.Viruses · 2023Review
- Early-career research education mentoring: a successful program in NeuroHIV and mental health (TRNAMH).NeuroImmune pharmacology and therapeutics · 2023Article
- Evidence for neuropsychological health disparities in Black Americans with HIV disease.The Clinical neuropsychologist · 2022Article
- HIV-Associated Neurocognitive Disorder (HAND): Obstacles to Early Neuropsychological Diagnosis.International journal of general medicine · 2022Review
- Misdiagnosis of HIV With Toxoplasmosis Encephalopathy With Progressive Memory Loss as the Initial Symptom: A Case Report.Frontiers in neurology · 2022Article
- International HIV Dementia Scale for HIV-Associated Neurocognitive Disorders: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
- Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure.Retrovirology · 2021Review
- Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.Journal of AIDS and HIV treatment · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of combination antiretroviral treatment (cART) has significantly reduced the mortality secondary to opportunistic infections in HIV patients by restoring the immune system. In the central nervous system (CNS), there has also been benefit with a marked reduction of HIV associated dementia. However, the milder forms of HIV associated neurocognitive disorder (HAND), namely asymptomatic neurocognitive impairment and mild neurocognitive disorder, remain prevalent in the cART era. In this article, we will discuss how cART interacts with HAND in terms of clinical characteristics and biomarkers. We will then review the outcomes of recent clinical studies focused on the CNS penetrating antiretroviral regimens and some novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.